Navigation Links
ViroPharma To Acquire Lev Pharmaceuticals
Date:7/15/2008

Additionally, ViroPharma agreed to make a $20 million investment in Lev, at signing, by purchasing 9,661,836 shares of Lev common stock at a 10 percent premium to the five day average closing price of Lev's shares for the period ending Friday, July 11, 2008, sold pursuant to Lev's effective registration statement on Form S-3.

J.P. Morgan Securities Inc. advised ViroPharma and DLA Piper acted as legal counsel. In addition, Piper Jaffray & Co. provided a fairness opinion to ViroPharma's board of directors. J.P. Morgan Securities Inc., as successor to Bear, Stearns & Co. Inc., advised Lev and provided a fairness opinion to Lev's board of directors. Willkie Farr & Gallagher LLP and Becker & Poliakoff, LLP acted as legal counsel to Lev.

Conference Call and Webcast Information

ViroPharma will host a live teleconference and webcast (featuring slide presentation) with senior management to discuss the strategic acquisition of Lev Pharmaceuticals on Tuesday, July 15, 2008 at 10:30 a.m. ET. Members of Lev Pharmaceuticals senior management will be available during the question and answer period. To participate in the conference call, please dial 888-299-4099 (domestic) and 302-709-8337 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

Alternatively, the live webcast of the conference call and slide presentation can be accessed via ViroPharma's website at http://www.viropharma.com. Windows Media or Real Player will be needed to access the webcast. An audio archive will be available at the same address until August 1, 2008.

Cinryze(TM) Regulatory Status

On May 2, 2008, the Blood Products Advisory Committee (BPAC) to the U.S. Food and Drug Administration (FDA) voted unanimously that there is sufficient evidence of the safety and efficacy for the approval of Cinryze for the prophylactic treatment of HAE. Th
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma Provides 2008 Outlook
3. ViroPharma to Present at the BIO CEO & Investor Conference
4. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... WriteResult, a premier provider of ePRO ... University’s School of Public Health and New Haven Farms ... 4 month-long project. The goal of the study was ... with free access to fresh produce and nutrition education ... like high blood pressure, diabetes and weight gain. Patients ...
(Date:3/25/2015)... ROCKVILLE, Md. , March 25, 2015 ... for the Vaccine Industry Excellence (ViE) Award "Best Clinical ... second consecutive year that Optimal has been selected as ... World Vaccine Congress, receiving a "Highly Recommended" distinction in ... generate recognition of the efforts, accomplishments, and positive contributions ...
(Date:3/25/2015)... 25, 2015 Accelovance, a therapeutically focused contract ... "Best Contract Research Organization" at the upcoming Vaccine Industry ... This is the eighth consecutive year ... award, winning for "Best Contract Research Organization" in 2009, ... in 2013. "We,re excited to be a ...
(Date:3/25/2015)... CA (PRWEB) March 25, 2015 ... for Novel Mechanism of Action in Neuromuscular Diseases ... 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced the ... skeletal muscle troponin activator tirasemtiv in the journal ... Phase IIa “Evidence of Effect” or hypothesis-generating clinical ...
Breaking Biology Technology:Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
... ANNAPOLIS, Md., June 28, 2011 PharmAthene, Inc. (NYSE ... Company was added to the Russell Global Index and ... comprehensive set of U.S. and global equity indexes on ... performance of the 3,000 largest U.S. companies based on ...
... research is challenging a widely held assumption on the best ... , Sarah "Misa" Runnells, claim is weighty enough to be ... ONE . , At issue is the best way to ... up to 800,000 years old. Such remains tend to be ...
... is building its reputation as a bioscience center with ... Healthcare of Atlanta, two Metro Atlanta Chamber (MAC) board ... "Atlanta has a thriving bioscience community, and this pediatric ... will benefit patients not just in Georgia, but throughout ...
Cached Biology Technology:PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index 2PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index 3PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index 4Undergraduate research fires salvo in simmering scientific controversy 2MAC Members Grow Atlanta's Bioscience Reputation 2MAC Members Grow Atlanta's Bioscience Reputation 3
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... Latin America . Annual estimates and forecasts ...
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
(Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... home after years spent at sea, a magnetic map is ... to an analysis of data collected over 56 years and ... a Cell Press publication. "To find their way back ... the magnetic field that exists where they first enter the ...
... February 7, 2013 ParticipACTION, the national voice of ... Children,s Hospital of Eastern Ontario (CHEO) Research Institute are ... awarded a Queen Elizabeth II Diamond Jubilee Medal from ... individuals who have distinguished themselves from others through their ...
... DNA sequencing has led to enormous advancements in the ... genetic information to gain valuable knowledge about causative and ... future treatments. But the wider availability of such information ... revealing personal information. Researchers from Tel Aviv University ...
Cached Biology News:Magnetic map guides salmon home 2Queen's Diamond Jubilee Medal for obesity research expert 2A privacy risk in your DNA 2A privacy risk in your DNA 3
...
...
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
Request Info...
Biology Products: